A capsule that meets the digestive tract directly.
Compounded oral BPC-157 delivered directly into the digestive tract, with a clinician deciding whether capsule or injection fits the case.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
About 10 minutes. No charge unless your clinician approves.
The tissue that never gets a day off.
The intestinal lining lives under constant pressure. Food, digestive chemistry, medications, microbes, and ordinary mechanical stress all pass through the same tissue, while that tissue has to keep renewing itself underneath the workload.
That makes the gut a very specific repair environment, and oral BPC-157 is designed for that conversation.
BPC-157 is a synthetic, stabilized 15-amino-acid fragment sequence modeled on a protective protein found naturally in the stomach lining. The body makes the original protein, not BPC-157 itself. The oral form uses the same BPC-157 molecule as the injectable preparation, delivered directly into the digestive tract.
In published animal research, orally administered BPC-157 improved intestinal repair and strengthened healing tissue at surgical anastomoses.12 The digestive tract is more than a convenient route for this molecule. It is part of the biological reason the oral formulation is interesting.
Oral BPC-157 is not an easier version of the injection. The capsule meets the digestive tract directly, while the format comparison and evidence limits give you and your clinician a clearer route decision.
For the digestive baseline you kept adapting around.
Your Safe-Food List Keeps Shrinking
Foods you once ate without thinking now require negotiation. The issue is no longer one trigger. It is how much attention digestion demands from the rest of your life.
Everything Changed After the Antibiotics
The prescription ended. The new digestive baseline did not. You learned to work around it, and now you want the tissue itself included in the medical conversation.
The Stomach Paid for Another Treatment
Anti-inflammatory medication solved one problem while your digestive tract absorbed part of the cost. Both things can be true, and the second one deserves its own plan.
Compounded BPC-157 is not an FDA-approved drug product. Whether it is appropriate for you is determined by a licensed provider from your full Assessment.
This might not be the right fit if:
- Active or suspected malignancy, or a history of cancer without oncology clearance
- Pregnancy or breastfeeding
- Known hypersensitivity to any component of the preparation
- Under 18
- Undiagnosed gastrointestinal bleeding, or any change in bowel habit that has not been evaluated
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
BPC-157 Oral, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- The same BPC-157 molecule used in the injectable preparation, compounded here as an oral capsule
- A licensed provider reviews your symptoms, medical history, medications, and full care plan before prescribing
- Dose and duration are individualized, with follow-up built into the plan
- Provider review, the prescription if approved, pharmacy, and shipping handled inside one plan.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Gut Health.
Wolverine 2.0
Add the inflammation layer.
A compounded three-peptide prescription that adds a distinct inflammation and comfort layer to the recovery conversation.
Do not use if you have
- Active or suspected malignancy
Serious risks
- BPC-157 acts on blood vessel formation, so providers screen carefully for any history of cancer
Commonly reported
- Mild and mostly digestive
Because it is a capsule
- The published work on the capsule measures what happens inside the digestive tract, so for a tendon or a joint your provider may recommend the injection instead
Human safety data is limited, which is the reason this sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Route should match the reason treatment is being considered. The oral formulation puts BPC-157 directly into the digestive tract, while the injectable formulation is used in the broader recovery-repair conversation. Your provider makes that decision from your Assessment rather than asking you to choose a route at checkout.
In July 2026 an FDA advisory committee voted to recommend BPC-157 for pharmacy compounding. That recommendation is advisory and the agency has not yet acted on it. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
Digestive problems that took years to become part of your baseline do not come with a responsible one-size-fits-all timeline. Your provider sets expectations from your history and adjusts from what actually happens after treatment starts.
A capsule does not become medicine because the label says BPC-157. Here, a licensed provider decides whether the molecule belongs in your care and a licensed US pharmacy compounds it to your individual prescription. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.F4 Testing has found wide variation in purity and in how much of the compound is actually in the product. The difference is not a more polished bottle. It is a prescriber, a pharmacy of record, and medical accountability around what you are taking.
Any time, before your renewal date. No phone calls required.
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, and FDA Warning Letter to Gram Peptides, March 31, 2026.